Spexis Announces Usd $2.5 Million Capital Commitment To Support The Upcoming Phase 3 Colifin® Studies

Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies

August 14, 2023

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced a capital commitment totaling USD $2.5 million with participation from SPRIM Global Investments (SGI) and institutional investors to fund the upcoming Phase 3 ColiFin® studies, beginning with the COPILOT study which is expected to initiate in the third quarter of 2023.

Latest News

Spexis Announces Usd $2.5 Million Capital Commitment To Support The Upcoming Phase 3 Colifin® Studies

Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies

August 14, 2023

Readout Ai Secures Pre Seed Funding To Decrease The Time From Clinical Trial Data To Clinical Trial Insight

DIGITAL CLINICAL SOLUTION

Readout AI Secures Pre-Seed Funding to Decrease the Time from Clinical Trial Data to Clinical Trial Insight

July 14, 2023

Sprim Global Investments Pte. Ltd. Completes Equity Investment In Uk Specialist Clinical Trial Site, Vctc Ltd.

DIGITAL CLINICAL SOLUTION

SPRIM Global Investments Pte. Ltd. completes equity investment in UK specialist clinical trial site, VCTC Ltd.

May 26, 2023

Obviohealth Signs R&d Partnership With A Star To Identify And Develop Novel Digital Biomarkers

DIGITAL CLINICAL SOLUTION

ObvioHealth Signs R&D Partnership with A*STAR to Identify and Develop Novel Digital Biomarkers

May 3, 2023

Spexis Announces Closing Of Capital Commitment Of Usd 4.5 Million From Sprim Global Investments (sgi) To Enable Initiation Of Colifin® Phase 3 Study

Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study

April 18, 2023

Data Vantage | Aum Biosciences, Scg Cell Therapy, Blood And Hello Health Disclose Updates

AUM Biosciences, SCG Cell Therapy, Blood And Hello Health Disclose Updates

April 6, 2023

1nhealth Launches Site Advisory Board To Prioritize Site Voice

DIGITAL CLINICAL SOLUTION

1nHealth Launches Site Advisory Board to Prioritize Site Voice

March 28, 2023

Stalicla And Firefly Neuroscience Enter Partnership Agreement For The Development Of Electroencephalogram (eeg) As A Biomarker For Subgroups Of Patients With Asd

STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

March 27, 2023

Obviohealth To Conduct A Pioneering Decentralized Clinical Trial On The Mi Helper Device For Treatment Of Migraine

DIGITAL CLINICAL SOLUTION

ObvioHealth to Conduct a Pioneering Decentralized Clinical Trial on The Mi-Helper Device for Treatment of Migraine

March 16, 2023

Jaguar Health Announces Initial Close In Private Placement Financing Round For Napo Therapeutics S.p.a.

Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.

February 9, 2023

Spexis And Sprim Global Investments (sgi) Announce Plans For Clinical Trial Partnership To Fund Up To Half Of The Projected Phase 3 Clinical Development Costs Of Colifin®

Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®

February 8, 2023

Stalicla Signs Exclusive In Licensing Agreement For Late Stage Clinical Neuropsychiatric And Neurodevelopmental Disorder Treatment

STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment

January 9, 2023

Regask Announces Us$10m Series A Funding Round Led By Monograph Capital To Accelerate Its Growth

DIGITAL CLINICAL SOLUTION

RegASK announces US$10m Series A Funding Round led by Monograph Capital to accelerate its growth

December 15, 2022

Aum Biosciences, A Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans To Become A Public Company Via Merger With Mountain Crest Acquisition Corp. V

AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V

October 20, 2022

Stalicla Sa And Evgen Pharma Plc Ink $160.5m Licensingdeal For Sfx 01

Stalicla SA and Evgen Pharma plc ink $160.5m licensing deal for SFX-01

October 12, 2022

Aum Biosciences Receives Fda Orphan Drug Designation For Aum601 For The Treatment Of Solid Tumors With The Ntrk Fusion Gene

AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTRK Fusion Gene

August 18, 2022

Obviohealth Ranked On Inc. 5000's List Of Fastest Growing Private Companies For Second Consecutive Year

DIGITAL CLINICAL SOLUTION

ObvioHealth Ranked on Inc. 5000’s List of Fastest Growing Private Companies for Second Consecutive Year

August 16, 2022

Treos Bio Announces First Patient Dosed In Phase 2 Trial Of Polypepi1018 In Combination With Roche’s Pd L1 Inhibitor For The Treatment Of Metastatic Colorectal Cancer

Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer

June 27, 2022

Fibronostics Secures Financing, Announces New Ceo

Fibronostics Secures Financing, Announces New CEO

June 15, 2022

Liverfast Can Be Better Than The Gold Standard Liver Biopsy, Because It Can Predict Mortality And Morbidity Of Patients.

DIGITAL CLINICAL SOLUTION

LIVERFASt can be better than the gold standard liver biopsy, because it can predict mortality and morbidity of patients.

April 2, 2022

DIGITAL CLINICAL SOLUTION

Faster, safer, more accurate trials.

March 5, 2022

Sprim Global Investments Names Susan Dallabrida As Chief Executive Officer Of Sprim Consultancy

R&D SERVICES/CRO

SPRIM Global Investments names Susan Dallabrida as Chief Executive Officer of SPRIM Consultancy

February 8, 2022

Digital Heath 150 2021

DIGITAL CLINICAL SOLUTION

The Digital Health 150: The Top Digital Health Companies Of 2021

December 8, 2021

GHO Capital Acquires Genesis Research, a Pioneer in Tech-enabled Real-World Evidence and HEOR Services

November 16, 2021

AUM Biosciences announces closing of $27 million in a “Series A” Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies

October 12, 2021

Objectivegi Announces Name Change To Objectivehealth

DIGITAL CLINICAL SOLUTION

ObjectiveGI Announces Name Change to ObjectiveHealth

September 14, 2021

Obviohealth Raises $31 Million, Adds Two Strategic Partners To Bolster Capabilities And Drive Growth Globally

DIGITAL CLINICAL SOLUTION

ObvioHealth Raises $31 Million, Adds Two Strategic Partners to Bolster Capabilities and Drive Growth Globally

July 1, 2021

Obviohealth Announces A Groundbreaking Partnership With Dedalus Group To Unite Real World & Clinical Trial Data

DIGITAL CLINICAL SOLUTION

ObvioHealth Announces a Groundbreaking Partnership with Dedalus Group to Unite Real World & Clinical Trial Data

June 7, 2021

Leveraging Next Gen Tools In Rare Disease Research

R&D SERVICES/CRO

Leveraging Next-Gen Tools in Rare Disease Research

March 1, 2021

DIGITAL CLINICAL SOLUTION

Genesis Research Announces Acquisition of Evid Science

January 7, 2021

Fibronostics Raises $8 Million in Series A Financing

August 24, 2020

Fibronostics Appoints Dr. Stephen A. Harrison To Its Board Of Advisors

Fibronostics Appoints Dr. Stephen A. Harrison to its Board of Advisors

August 5, 2020

The Critical Need For Virtual Covid 19 Clinical Trials And Patient Training

DIGITAL CLINICAL SOLUTION

The Critical Need for Virtual COVID-19 Clinical Trials and Patient Training

June 23, 2020

Obviohealth And Hôpital Paris Saint Joseph Announce Partnership To Track Covid 19 In Oncology Patients

DIGITAL CLINICAL SOLUTION

ObvioHealth and Hôpital Paris Saint-Joseph Announce Partnership to Track COVID-19 in Oncology Patients

June 18, 2020

Travecta Therapeutics Announces It Has Closed Its Oversubscribed Series A Round At $27 Million

Travecta Therapeutics Announces it has Closed its Oversubscribed Series A Round at $27 Million

June 11, 2020

Sprim Partners With Health Catalyst To Analyze Covid 19 Impact On Nash And Nafld

R&D SERVICES/CRO

SPRIM Partners with Health Catalyst to Analyze COVID-19 Impact on NASH and NAFLD

June 8, 2020

DIGITAL CLINICAL SOLUTION

ObvioHealth Secures $17 Million in Latest Investment Round

May 20, 2020

Travecta Therapeutics Secures $15 Million in Financing

May 12, 2020

Ventures Day Singapore 2020 Post Event Highlights

Ventures Day Singapore 2020: Post-event highlights

February 10, 2020

Ac Health Announces Investment In Fibronostics

AC Health Announces Investment in Fibronostics

June 7, 2019

Sprim’s Quarterly Ventures Day Meeting In New York

SPRIM’s Quarterly Ventures Day Meeting in New York

March 21, 2019

Objective Gi Funding Announcement

DIGITAL CLINICAL SOLUTION

Objective GI Funding Announcement

January 29, 2019

Tks 1 Investor Day 2019 In Singapore Post Event Highlights

TKS 1 Investor Day 2019 in Singapore: Post Event Highlights

January 28, 2019

Regask, A Healthcare Regtech Startup, Secures Venture Capital Funding In A Seed Round To Pursue Growth

DIGITAL CLINICAL SOLUTION

RegASK, a Healthcare RegTech Startup, Secures Venture Capital Funding in a Seed Round to Pursue Growth

January 15, 2019

Tikehau Capital And Sprim

SPRIM and Tikehau Capital Join Forces with New Singapore-based Life Sciences VC Fund

November 15, 2018

Evid Science Receives Seed Capital To Advance Clinical Ai Platform

DIGITAL CLINICAL SOLUTION

Evid Science Receives Seed Capital to Advance Clinical AI Platform

November 15, 2018

Obviohealth Raises $3 Million In Series A Funding

DIGITAL CLINICAL SOLUTION

ObvioHealth Raises $3 Million in Series A Funding

March 23, 2018

This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.